Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
6
×
Tags
biotech
life sciences
national
6
×
national blog main
europe blog main
clinical trials
national top stories
fda
new york blog main
abbvie
allergan
biogen
boston blog main
boulder/denver blog main
boulder/denver top stories
brexit
cancer
covid-19
deerfield management
detroit blog main
detroit top stories
drug discovery
drugs
eli lilly
europe
europe top stories
falsified medicines
gilead sciences
indiana blog main
indiana top stories
innovation
ipo
labeling
melinta therapeutics
mhra
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
regulations
What
medicines
6
×
plans
bio
brexit
charting
choppy
course
covid
dynamic
end
fda
ipo
new
period
post
regulation
regulatory
reveals
roundup
transition
treat
uk
abcellera
abcellera’s
acquisitions
activity
adults
allergan
announced
antibodies
antibody
approvals
approved
based
biogen
biologics
biotech
ceo
clamped
class
Language
unset
6
×
Current search:
medicines
×
photo
×
unset
×
national
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
AbCellera’s Coronavirus “Neutralizing” Antibody Leads Enter Screening
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
